Copyright
©The Author(s) 2022.
World J Hepatol. Sep 27, 2022; 14(9): 1718-1729
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1718
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1718
NAS | SAF | ||
Component | Scoring range | Component | Scoring range |
Steatosis | 0-3 | Steatosis | 0-3 |
Lobular Inflammation | 0-3 | Activity (lobular inflammation + ballooning) | 0-8 |
Hepatocyte ballooning | 0-3 | ||
Fibrosis (separate from NAS) | Fibrosis (uses the same fibrosis staging as NAS) | ||
F0 | None | ||
F1 | Perisinusoidal or periportal | ||
F1A | Mild, zone 3, perisinusoidal | ||
F1B | Moderate, zone 3, perisinusoidal | ||
F1C | Portal/periportal | ||
F2 | Both perisinusoidal and portal/periportal | ||
F3 | Bridging fibrosis | ||
F4 | Cirrhosis |
- Citation: Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729
- URL: https://www.wjgnet.com/1948-5182/full/v14/i9/1718.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i9.1718